Snoozeal® | Daytime Sleep Therapy

A clinically proven therapy that targets the root cause of snoring and mild sleep apnoea.

Snoozeal® is a non-invasive intraoral neuromuscular stimulation device with clinically proven reduction of primary snoring and mild obstructive sleep apnoea.

Snoozeal® challenges the wisdom of conventional snoring solutions. It is the first, unique daytime treatment for sleep disordered breathing that uses an entirely novel and original method – physiologically retraining the airway against collapse.

Now patients can benefit from this convenient and effective therapy so that they and their partners can get a better night’s sleep.

The Snoozeal® Transoral Neuromuscular Therapy Device

Improve patients quality of life, sleep and relationships.

Snoozeal® is a user controllable neuromuscular electrical stimulator (NMES) that delivers a mild electrical current with defined frequencies to stimulate and improve muscle function in the mouth and tongue.

Unlike traditional snoring therapies, Snoozeal® strengthens tongue and throat muscle tone, to prevent excessive muscle relaxation during sleep, reducing airway collapse.

A daytime therapy with no night-time wearable necessary for a better night’s sleep.

Snoozeal® has been clinically proven to improve the quality of sleep by reducing snoring and sleep apnoea significantly, when used for 20 minutes, once a day for 6 weeks 1-3

Clinically proven efficacy for primary snoring and mild sleep apnoea

Original Cohort Clinical Study

Location: Essen, Germany and Nottingham, UK
Cohort: 30 patients
Documents: CHEST Presentation, Publication, Original Paper

Prospective Cohort Clinical Study with Objective Assessments

Location: London, UK
Cohort: 50 patients


    1. E.Wessoleck et al. Intraoral electrical muscle stimulation in the treatment of snoring. Somnologie (Berl). 2018; 22(Suppl 2): 47–52
    2. A.Sama et al. Daytime Intraoral Neurostimulation with Snoozeal® for treatment of Snoring and Mild Sleep Apnea. CHEST Annual Meeting Notes, 2018
    3. Prospective cohort study of 50 patients with snoring or mild OSA (Apnea- Hypopnea Index (AHI) <15) with 46 completed the trial. Objective snoring and respiratory parameters were recorded with 2 consecutive WatchPat night sleep studies before and after the use of the device. An intra-oral tongue stimulator (Snoozeal®) device was used for 20mins, once a day for 6-week period

Request product information or brochures, book a product trial or arrange a product demonstration, send us a message, ask us a question or make a comment.